Halozyme Therapeutics has secured a significant legal victory in its ongoing patent dispute with pharmaceutical giant Merck & Co. A German court has granted an injunction against Merck’s sales of Keytruda, blocking the drug’s distribution in the country amid allegations of patent infringement. The ruling marks a critical development in the high-stakes battle over the rights to the blockbuster cancer treatment and underscores the complex legal challenges facing the pharmaceutical industry in protecting intellectual property. This decision, reported by The Wall Street Journal, highlights the continued litigation entanglements surrounding Keytruda as companies jockey for control over the lucrative immunotherapy market.
Halozyme Secures Injunction Against Merck in German Keytruda Patent Dispute
In a significant ruling, a German court has sided with Halozyme, issuing an injunction that bars Merck & Co. from infringing on Halozyme’s patent related to the biologic processes used in…
—-
Author : Ava Thompson
Publish date : 2025-12-05 07:08:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
